Article: FDA, SEC link up on false statements to public.

Dear Reader,

FDA and the Securities and Exchange Com-mission have developed a closer partnership, whereby FDA will provide SEC with information about potential false and misleading statements about drugs, devices and other agency-regulated products.

The effort appears to have been spearheaded by the Martha Stewart-ImClone insider trading case. In that matter, ImClone's former top executives concealed the fact from investors that FDA would not be approving its drug, Erbitux. Yet, the top executives allegedly sold ImClone stock and tipped off investors such as Stewart to the stock's decline.

However, the new working agreement with SEC has broader ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!